Fingerprint
Dive into the research topics where Natalie Baker is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Drivers of Crimean-Congo Hemorrhagic Fever in Natural Host and Effects of Control Measures, Bulgaria
Limon, G., Tchakarova, S. R., Ludi, A., Alexandrov, T., Christova, I., Petkova, P., Maze, E., Thomas, K., Baker, N., England, M., Browning, C., Wilsden, G., Belij-Rammerstorfer, S., Lambe, T., Jolles, A., Carroll, M., Hewson, R., Gubbins, S., Charleston, B. & Lyons, N. A., Sept 2025, In: Emerging Infectious Diseases. 31, 9, p. 1738-1746 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Development of anti-Crimean-Congo hemorrhagic fever virus Gc and NP-specific ELISA for detection of antibodies in domestic animal sera
Belij-Rammerstorfer, S., Limon, G., Maze, E. A., Hannant, K., Hughes, E., Tchakarova, S. R., Alexandrov, T., Mmbaga, B. T., Willett, B., Booth, G., Lyons, N. A., Baker, N., Thomas, K. M., Wright, D., Saunders, J., Browning, C., Wilsden, G., Carroll, M., Hewson, R. & Charleston, B. & 2 others, , 25 Aug 2022, In: Frontiers in Veterinary Science. 9, 913046.Research output: Contribution to journal › Article › peer-review
Open Access8 Citations (Scopus) -
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
COV-BOOST study group, Aug 2022, In: The Lancet Infectious Diseases. 22, 8, p. 1131-1141 11 p.Research output: Contribution to journal › Article › peer-review
Open Access156 Citations (Scopus) -
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (Nature Medicine, (2021), 27, 2, (270-278), 10.1038/s41591-020-01194-5)
the Oxford COVID Vaccine Trial Group, 1 Jun 2021, In: Nature Medicine. 27, 6, p. 1116 1 p.Research output: Contribution to journal › Comment/debate
Open Access10 Citations (Scopus) -
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
the Oxford COVID Vaccine Trial Group, Nov 2021, In: Nature Medicine. 27, 11, p. 2032-2040 9 p.Research output: Contribution to journal › Article › peer-review
Open Access928 Citations (Scopus)